Inhibition of lipopolysaccharide-initiated activation of serum complement by polymyxin B.
Treatment of bacterial lipopolysaccharides (endotoxins) isolated from Salmonella minnesota R595 or purified lipid A with the antibiotic polymyxin B has been demonstrated to abrogate the ability of these molecules to activate serum complement. The inhibition is a function of the ratio of polymyxin B to lipopolysaccharide.
D000818:Animals; D003165:Complement System Proteins / Q000502:physiology*; D006461:Hemolysis / Q000187:drug effects; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors*; D011113:Polymyxins / Q000494:pharmacology*; D011135:Polysaccharides, Bacterial / Q000037:antagonists & inhibitors*; D011817:Rabbits; D012475:Salmonella
D008070:Lipopolysaccharides; D011113:Polymyxins; D011135:Polysaccharides, Bacterial; D003165:Complement System Proteins